The projected fair value for PTC Therapeutics is US$83.21 based on 2 Stage Free Cash Flow to Equity PTC Therapeutics is estimated to be 43% undervalued based on current share price of US$47.50 Our ...

For Q4’25 specifically, PTC anticipates operating cash flow of $93 million to $98 million and free cash flow of $90 million to $95 million. To achieve its full-year ARR growth target of 8% to 9%, the ...

Wondering if PTC at around $175 is quietly setting up a value opportunity, or if the easy gains are already gone? This breakdown will help you decide whether it still deserves a spot on your watchlist ...

PTC’s aftermarket stock price increased by 0.59% to $198.43 following the earnings release, indicating positive investor sentiment despite the stock trading below its 52-week high of $219.69. Detailed ...

PTC Therapeutics, Inc. (PTCT), a biopharmaceutical company specializing in rare disorders, stands at a critical juncture as it navigates a complex landscape of regulatory decisions, product launches, ...

The projected fair value for PTC is US$268 based on 2 Stage Free Cash Flow to Equity PTC's US$141 share price signals that it might be 48% undervalued Analyst price target for PTC is US$162 which is ...

Analyst price target for PTC is US$162 which is 40% below our fair value estimate Does the September share price for PTC Inc. (NASDAQ:PTC) reflect what it's really worth? Today, we will estimate the ...